
Hematology-OncologyAllo-HSCThematologic malignancy
Allogeneic Stem Cell Transplantation After 70: Japanese Registry Data Define Who May Benefit Most
By MedXY|Jun 19, 2026
A Japanese registry study of 929 patients aged 70+ identified six predictors of worse survival after allo-HSCT and created a simple score that sharply stratified 2-year overall survival from 57.1% to 2.5%.

